Novel anti-HIV drug Genvoya® received US regulatory approval, JT’s partner Gilead Sciences announced
November 6, 2015 - A New Drug Application for once-daily single tablet regimen Genvoya
(elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and tenofovir alafenamide (TAF) 10mg)for the
treatment of HIV-1 infection has been approved by the U.S. Food and Drug Administration (FDA). Genvoya
is the first TAF-based regimen to receive FDA approval. Japan Tobacco Inc. (JT) (TSE:2914) and Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551)
announced that a statement has been issued to this effect by Gilead Sciences, Inc. (Gilead) on November 5, 2015, the U.S. local time.
Genvoya is indicated as a complete regimen for the treatment of HIV-1 infection in adults and
pediatric patients 12 years of age and older who have no antiretroviral treatment history or to
replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no
history of treatment failure and no known substitutions associated with resistance to the
individual components of Genvoya. No dosage adjustment of Genvoya is required in patients
with estimated creatinine clearance greater than or equal to 30 mL per minute. TAF is a novel targeted prodrug of tenofovir
that has demonstrated high antiviral efficacy similar
to and at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate,
TDF), as well as improvement in surrogate laboratory markers of renal and bone safety as
compared to TDF in clinical trials in combination with other antiretroviral agents. Data show
that because TAF enters cells, including HIV-infected cells, more efficiently than TDF, it can be
given at a lower dose and there is 91 percent less tenofovir in the bloodstream. Following a positive opinion by the scientific committee of the European Medicines Agency,
Genvoya is now under review by the European Commission.
In addition to Genvoya, another investigational, TAF -based, fixed-dose combination of emtricitabine 200 mg
and tenofovir alafenamide 25 or 10 mg (F/TAF) for use in combination with other antiretroviral agents
is also under evaluation by the FDA and the European Medicines Agency.
JT holds the exclusive rights to develop and commercialize Genvoya and F/TAF in Japan, and
the Company is aiming to submit a New Drug Application for Genvoya in
the first quarter of FY 2016, to the Japanese Ministry of Health, Labour and Welfare.
Under the terms of the agreement between JT and Toriion March 2, 2015, Toriiholds exclusive
rights to market Genvoya and F/TAF in Japan, subsequent to JT’s obtaining manufacturing and
marketing approval from the country’s authorities.
* Elvitegravir was discovered by JT. The Company licensed elvitegravir to Gilead in 2005 with
exclusive rights to develop and commercialize in all countries of the world, excluding Japan,
where JT retains rights.
* TAF and TAF-based regimens are investigational products and have not been determined safe or efficacious in Japan
*Genvoya and Viread are registered trademark of Gilead.
###
Lei Zhang, a biomedical engineering graduate student in Tripathi's lab is the lead author on the paper. In addition to Zhang, Coetzer, Tripathi, and Kantor, the paper's other authors are Jingjing Wang (now at PerkinElmer) and Stephanie Angione (now at Massachusetts General Hospital).
The National Institute of Allergy and Infectious Diseases (grant P30AI042853), the Lifespan/Tufts/Brown CFAR, and Brown University funded the research.
Japan Tobacco Inc. is a leading international tobacco company. Its products are sold in over 120 countries and its
internationally recognized brands include Winston, Camel, Mevius
and LD. With diversified operations, JT is also
actively present in pharmaceuticals and processed foods. The company’s revenue was
¥
2.154 trillion (US$17,867
million(*)) in the fiscal year ended December 31, 2014(**).
*Translated at the rate of
¥
120.55
per $1, as of December 31, 2014
**Due to a change in the accounting period from March 31 to December 31, the fiscal year 2014 covered nine
months for Japanese domestic businesses and 12 months for the
consolidated subsidiaries which operate the
Group’s int
ernational tobacco business. On a comparable full calendar year basis, revenue was
¥
2.433 trillion
(US$20,186 million(*)).
Contacts
for Japan Tobacco Inc.:Contact for Torii Pharmaceutical Co., Ltd.:
Ryohei Sugata, General Manager
Planning
Department (Public Relations)
Media and Investor Relations Division
Torii Pharmaceutical Co., Ltd.
Japan Tobacco
Inc. Tokyo: +81
-
3
-
5572
-
4292
Tokyo: +81
-
3
-
3231
-
6814
E
-
mail:
jt.media.relations@jt.com
Contact for Torii Pharmaceutical Co., Ltd.:Ryohei Sugata, General Manager
Planning
Department (Public Relations)
Media and Investor Relations Division
Torii Pharmaceutical Co., Ltd.
Japan Tobacco
Inc. Tokyo: +81
-
3
-
5572
-
4292
Tokyo: +81
-
3
-
3231
-
6814
Source: https://www.jt.com/media/press_releases/2015/pdf/20151106_E01.pdf
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News |
